NEW YORK (GenomeWeb News) – Xceed Molecular has licensed the rights to use a gene signature for colon cancer from the Moffitt Cancer Center, the company said today.
The Wellesley, Mass.-based firm has purchased the worldwide, exclusive rights to use the gene signature to develop a molecular test that can predict patient prognosis for the disease, which Xceed said is diagnosed in over 100,000 Americans each year. Xceed will work with Tampa, Fla.-based Moffitt researchers to complete clinical development and validation of the signature, which uses biopsy tissues from colonoscopy to predict the chances of return of the disease.
The collaborators hope to develop a list of genes that Xceed will include in its TipChip colon cancer microarray device that runs on the company’s Ziplex System. Xceed said that it will run the first samples in its Expression Services Lab in Toronto to optimize the performance of the signature on the Ziplex System. The company also will provide Moffitt with a Ziplex for additional validation studies.
“We have high hopes that the gene signature that we are developing may be useful in helping physicians to make critical treatment decisions, but the great challenge in this field has been turning promising biomarkers into routine diagnostic tools,” Tim Yeatman, a Moffitt researcher who helped develop the colon cancer gene signature, said in a statement.